Latest news

New film from Eiffage about Ironhand®

Bioservo has finished a successful long term trial with Toyota Motor North America

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

08 Nov, 2019

Nomination Committee appointed before the annual general meeting of Bioservo 2020

In line with the decision taken during the Annual General Meeting on May 6, 2019, Bioservo’s Chairman of the Board has contacted the company's largest owners to form a nomination committee. Counted as an owner is also a group of two or more shareholders (shareholder group) if they have notified the Chairman of the Board that they wish to participate in the work of the nomination committee together.

The following shareholders and representatives are part of the Nomination Committee, in addition to Anders Lundmark, Chairman of the Board:

  • Runar Bjørklund, nominated by Tellacq AB, also Chairman of the Nomination Committee
  • Tomas Ward, representing his private holding
  • Simon Josefsson, nominated by Simon Josefsson Datakonsult AB

The Nomination Committee shall submit proposals to the Chairman of the Annual General Meeting 2020 regarding the following:

  • Proposal for members of the Board of Directors
  • Proposal for the auditor
  • Proposal for the Chairman of the Board
  • Proposal regarding the Board remuneration, divided for the chairman and for other members of the board as well as remuneration for committee work
  • Proposed remuneration to the auditor
  • Proposal for Chairman of the Annual General Meeting
  • Guidelines for appointment of the election committee

Shareholders who wish to submit proposals to the Nomination Committee for the Annual General Meeting 2020 may do so to the Nomination Committee no later than February 28, 2020 by emailing to valberedningen@bioservo.com or by posting a letter addressed to Bioservo Technologies AB, Nomination Committee, Torshamnsgatan 35, 164 40 Kista.

About Bioservo Technologies
Bioservo Technologies AB (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimize the body’s endurance and performance, or for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8 528 00399, info@fnca.se is the Company’s Certified Adviser on Nasdaq First North Growth Market.

For more information, please visit www.bioservo.com